ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Organon and Co

Organon and Co (OGN)

13,39
0,03
( 0,22% )
Aktualisiert: 16:21:26

Organon and Co (OGN) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
13,39
( 0,22% )
Gebot
-
Fragen
-
Volumen
256.904
13,39 Tagesbereich 13,405
5,69 52-Wochen-Bereich 13,48
Marktkapitalisierung
Handelsende
13,36
Handelsbeginn
13,40
Letzter Handelszeitpunkt
16:21:49
Finanzvolumen
US$ 3.441.983
VWAP
13,3979
Durchschnittliches Volumen (3 Mio.)
US$ 8.623.697
Ausgegebene Aktien
262.600.862
Dividendenrendite (LTM)
0,08 (0,60%)
Kurs-Gewinn-Verhältnis
14,22
Gewinn pro Aktie (EPS)
0,94
Erlöse (LTM)
6,16B
Nettogewinn (LTM)
246M

Über Organon and Co

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comp... Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Jersey City, United States
Gegründet
2026
Organon and Co is listed in the Healthcare sector of the New York Börse with ticker OGN. The last closing price for Organon was US$13,36. Over the last year, Organon shares have traded in a share price range of US$ 5,69 to US$ 13,48.

Organon currently has 262.600.862 shares in issue. The market capitalisation of Organon is US$3,52 billion. Organon has a price to earnings ratio (PE ratio) of 14.22.

OGN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.020.14958863126413.3713.40513.35243481813.37700316CS
40.040.29962546816513.3513.4813.28339879813.3739411CS
126.98108.8923556946.4113.485.69913692911.27429114CS
266.2587.53501400567.1413.485.6969951979.94517256CS
523.8139.77035490619.5813.485.6958998209.46632184CS
156-7.16-34.841849148420.5524.085.69414531812.66650114CS
260-16.94-55.852291460630.3339.4755.69334020617.12963531CS

OGN - Frequently Asked Questions (FAQ)

What is the current Organon and Co share price?
The current share price of Organon and Co is US$ 13,39
How many Organon and Co shares are in issue?
Organon and Co has 262.600.862 shares in issue
What is the market cap of Organon and Co?
The market capitalisation of Organon and Co is USD 3,52B
What is the 1 year trading range for Organon and Co share price?
Organon and Co has traded in the range of US$ 5,69 to US$ 13,48 during the past year
What is the PE ratio of Organon and Co?
The price to earnings ratio of Organon and Co is 14,22
What is the cash to sales ratio of Organon and Co?
The cash to sales ratio of Organon and Co is 0,57
What is the registered address of Organon and Co?
The registered address for Organon and Co is 30 Hudson Street, Jersey City, New Jersey, 07302
What is the Organon and Co website address?
The website address for Organon and Co is www.organon.com
Which industry sector does Organon and Co operate in?
Organon and Co operates in the Pharmaceuticals sector

OGN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen